Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 1
2000 1
2003 1
2006 2
2007 1
2008 1
2009 3
2010 3
2011 3
2012 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses.
Alberini I, Del Tordello E, Fasolo A, Temperton NJ, Galli G, Gentile C, Montomoli E, Hilbert AK, Banzhoff A, Del Giudice G, Donnelly JJ, Rappuoli R, Capecchi B. Alberini I, et al. Among authors: hilbert ak. Vaccine. 2009 Oct 9;27(43):5998-6003. doi: 10.1016/j.vaccine.2009.07.079. Epub 2009 Aug 7. Vaccine. 2009. PMID: 19665606 Clinical Trial.
An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A. Del Giudice G, et al. Among authors: hilbert ak. Vaccine. 2006 Apr 12;24(16):3063-5. doi: 10.1016/j.vaccine.2006.01.015. Epub 2006 Jan 19. Vaccine. 2006. PMID: 16464520
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.
Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, Brauer V, Banzhoff A, Rappuoli R, Del Giudice G, Castellino F. Galli G, et al. Among authors: hilbert ak. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3877-82. doi: 10.1073/pnas.0813390106. Epub 2009 Feb 23. Proc Natl Acad Sci U S A. 2009. PMID: 19237568 Free PMC article. Clinical Trial.
Immunogenicity and reactogenicity of a combined fully liquid DTPw-HepB-Hib pentavalent vaccine in healthy infants: no clinically relevant impact of a birth dose of hepatitis B vaccine.
Gentile A, Umido V, Czerniuk P, Nacul J, Seigelchifer M, Hilbert AK, Yela U, Herzog C, Aeberhard U, Spyr C. Gentile A, et al. Among authors: hilbert ak. Int J Infect Dis. 2011 Jan;15(1):e24-9. doi: 10.1016/j.ijid.2010.09.004. Epub 2010 Nov 18. Int J Infect Dis. 2011. PMID: 21093342 Free article. Clinical Trial.
Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.
van Damme P, Kafeja F, Anemona A, Basile V, Hilbert AK, De Coster I, Rondini S, Micoli F, Qasim Khan RM, Marchetti E, Di Cioccio V, Saul A, Martin LB, Podda A. van Damme P, et al. Among authors: hilbert ak. PLoS One. 2011;6(9):e25398. doi: 10.1371/journal.pone.0025398. Epub 2011 Sep 30. PLoS One. 2011. PMID: 21980445 Free PMC article. Clinical Trial.
16 results